POLE and endometrial carcinoma: In colorectal and endometrial carcinoma, it was well demonstrated that MMR-D or POLE exonuclease domain mutation could lead to a marked increase of somatic mutations in tumors and predict response to anti-PD-L1 treatment [30,31,32].